SCHEMBL13824434

SCHEMBL13824434

O=CCOc1ccc2c(c1)/C(=C/CCN1CCC3(CC1)OCc1cc(Cl)ccc13)c1cccnc1CO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 2/20 0.48
▸ CHRM2 P08172 1/20 0.44
▸ CCR5 P51681 1/20 0.44
▸ S1PR5 Q9H228 1/20 0.40
▸ AVPR1A P37288 3/20 0.33
▸ KCNH2 Q12809 3/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ HTR2B P41595 2/20 0.32
▸ HRH1 P35367 2/20 0.32
▸ MCHR1 Q99705 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ ADRA2A P08913 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ ADRA2B P18089 1/20 0.32
▸ ADRA2C P18825 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12121845 0.91 CCR1 (0.51) CCR1CHRM2CCR5S1PR5KCNH2
SCHEMBL13824432 0.90 CCR1 (0.48) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL10287557 0.90 CCR1 (0.49) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL14579627 0.90 CCR1 (0.49) CCR1CHRM2CCR5S1PR5KCNH2
SCHEMBL14420122 0.90 CCR1 (0.49) CCR1CHRM2CCR5S1PR5KCNH2
SCHEMBL13824439 0.89 CCR1 (0.52) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL16312643 0.88 CCR1 (0.48) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL15478312 0.88 CCR1 (0.48) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL16312659 0.88 CCR1 (0.51) CCR1CHRM2CCR5S1PR5AVPR1A
SCHEMBL14419972 0.88 CCR1 (0.47) CCR1CHRM2CCR5S1PR5AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541365-B2 Chemokine receptor antagonists and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-06-02 — — US disclosed
US-7271176-B2 Chemokine receptor antagonists and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-09-18 — — US disclosed
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation THPO, NFATC1, HPGDS CCR1 19/4885CHRM2 615/4885CCR5 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback